On December 12 at 10:00 CET, InDex CEO Peter Zerhouni will give an overview of how the company sees the way forward towards phase III based on the successful phase IIb study CONDUCT with the drug candidate cobitolimod. The presentation concludes with a Q&A session together with InDex Pharmaceuticals...Read more
- Company presentation
- InDex Pharmaceuticals on Nasdaq First North Growth Market
- The share
- Interim Reports
- Annual Reports
- Press releases
- Capital Markets Day in Stockholm – April 25, 2018
- Financial calendar
- Nasdaq First North Growth Market Certified Adviser
- IR contact
Ulcerative colitis is a chronic inflammatory bowel disease of unknown cause.
Symptoms include frequent stools, diarrhea, blood in stool, abdominal pain, fever, weight loss and anemia. Standard treatment includes anti-inflammatory, immunosuppressive and biological drugs.
A substantial percentage of patients with moderate to severe active ulcerative colitis will not respond to available therapies or will eventually develop tolerance to treatment.
Cobitolimod (Kappaproct, DIMS0150) is a potential new medication for patients with moderate to severe active ulcerative colitis.
Cobitolimod is a first in class treatment that provides a local anti-inflammatory effect which in clinical trials has shown to result in significant improvements of the major clinical symptoms.
Cobitolimod has very limited systemic absorption. This gives the drug a favorable safety profile, in sharp contrast to many approved treatments.